Rebecca Elstrom

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Utility of FDG-PET scanning in lymphoma by WHO classification
    Rebecca Elstrom
    Abramson Family Cancer Research Institute of the University of Pennsylvania, Philadelphia, USA
    Blood 101:3875-6. 2003
  2. ncbi 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma
    Lapo Alinari
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 47:2096-101. 2006
  3. ncbi Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma
    Morton Coleman
    Division of Hematology Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
    Leuk Lymphoma 49:447-50. 2008
  4. ncbi Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma
    Peter Martin
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Hematol 45:126-32. 2008

Collaborators

Detail Information

Publications4

  1. ncbi Utility of FDG-PET scanning in lymphoma by WHO classification
    Rebecca Elstrom
    Abramson Family Cancer Research Institute of the University of Pennsylvania, Philadelphia, USA
    Blood 101:3875-6. 2003
    ..In contrast, FDG-PET detected disease in only 67% of MZL and 40% of PTCL. Comparison with bone marrow biopsies showed that FDG-PET was not reliable for detection of bone marrow involvement in any lymphoma subtype...
  2. ncbi 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma
    Lapo Alinari
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 47:2096-101. 2006
    ..Sensitivity of 18F FDG-PET for extra-nodal MALT was 81%. The data show that 18FDG-PET is a useful diagnostic tool in order to stage, restage or monitor disease in patients with extra-nodal MALT lymphoma...
  3. ncbi Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma
    Morton Coleman
    Division of Hematology Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
    Leuk Lymphoma 49:447-50. 2008
    ....
  4. ncbi Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma
    Peter Martin
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Hematol 45:126-32. 2008
    ..Each of these strategies has shown varying degrees of preclinical and clinical success. In this review we discuss the rationale for various strategies and report results from clinical trials employing these agents...